Its opioid dissed by FDA advisors, S.F. drugmaker abandons program
January 15, 2020 at 10:23 AM EST
The drug would have been the first new opioid in its class in more than 50 years.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.